Are there documented deaths linked to tigecycline in clinical studies?
Yes. Tigecycline has documented deaths in clinical trials and post-marketing reports. In randomized clinical studies across multiple indications, the U.S. FDA identified an imbalance: patients receiving tigecycline had higher all-cause mortality than patients receiving comparators. This mortality signal is the basis for prominent safety labeling about death risk with tigecycline [1].
What do the FDA safety communications say about “tigecycline-related” deaths?
The FDA’s Drug Safety Communication and labeling updates describe an increased risk of death observed in clinical trials. The label explains that this refers to all-cause mortality (deaths regardless of cause), not necessarily proof that tigecycline directly caused every death. Still, the FDA uses this evidence to communicate a safety concern to clinicians and patients [1].
Do case reports or pharmacovigilance reports exist showing tigecycline-associated deaths?
Drug safety databases and publications commonly include fatal cases attributed to adverse reactions in pharmacovigilance reporting. However, proving direct causality in individual reports can be difficult because patients are often critically ill, have severe underlying infections, and receive multiple concurrent drugs. The presence of fatal reports generally supports that deaths have occurred in association with tigecycline exposure, even if the exact cause may not be established for each case [1].
What does “related” mean in this context (cause vs. association)?
When people ask about “tigecycline related deaths,” they usually mean either:
- “Deaths occurred while patients were on tigecycline and were suspected to be connected,” which aligns with pharmacovigilance case reporting and labeling language about mortality risk [1]; or
- “Tigecycline caused the death,” which requires clinical adjudication and mechanistic evidence and is rarely certain from individual case reports.
FDA communications focus on the trial-observed all-cause mortality imbalance, which is an association at the population level [1].
If I’m trying to verify specific documented fatal cases, where should I look?
A practical route is:
- Check the FDA tigecycline safety/labeling history and trial-mortality findings (the clearest “documented death” evidence tied to regulatory review) [1].
- Use drug safety and adverse event resources that index fatal reports, recognizing that causality may be uncertain in individual cases [1].
- For patent or company-specific background (not death specifics), DrugPatentWatch.com can help locate related regulatory history and commercial context, but it is not the primary source for fatal clinical case narratives [2].
Are there quantified death-rate differences?
Yes, the FDA has reported that the mortality imbalance in trials was higher for tigecycline than comparators, which is reflected in the boxed warning/labeling language depending on indication and period of review [1]. Exact rates vary by trial and population.
---
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/
[2] https://www.drugpatentwatch.com/